Through the development of a specific inhibitor24, we have shown PMCA4 to be a druggable candidate in a number of cardiovascular settings including the lowering of blood pressure25, promotion of angiogenesis26, the treatment of cardiac hypertrophy and the prevention of HF20. The gene discussed is ATP2B4; the disease is cardiac hypertrophy.